奇正藏藥(002287.SZ):擬推2024年員工持股計劃
格隆匯9月26日丨奇正藏藥(002287.SZ)公佈2024年員工持股計劃,本員工持股計劃的資金來源為公司計提的長期激勵基金、員工合法薪酬、自籌資金或法律法規允許的其他方式。本員工持股計劃的資金總額不超過15,600.00萬元,其中公司計提的長期激勵基金不超過14,400.00萬元。公司不以任何方式向持有人提供墊資、擔保、借貸等財務資助。本員工持股計劃以“份”作為認購單位,每份份額為1.00元,員工必須認購整數倍份額,本員工持股計劃的份數上限為15,600.00萬份。
以2024年9月26日公司股票收盤價20.24元/股測算,本員工持股計劃通過二級市場購買所能持有的標的股份數量上限約為770.75萬股,佔公司現有總股本的比例為1.45%。最終標的股票的購買情況目前還存在不確定性,最終持有的股票數量以實際執行情況為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.